Cell growth inhibitor and screening method thereof
AssigneeThe University of Tokyo
InventorsSatoshi Inoue, Kenichi Takayama
Life of this patent
Estimating the term…
Abstract
An object is to provide a cell growth inhibitor also effective for androgen-independent prostate cancer. The present invention provides a cell growth inhibitor having, as an active ingredient, an expression inhibitor or function inhibitor of an antisense RNA (CTBP1-AS) expressed in the vicinity of an androgen receptor (AR) binding site of a C-terminal binding protein (CTBP1) gene.
Claims13
A cell growth inhibitor, which inhibits the growth of cells in which any of the following antisense RNAs (which will hereinafter be called “CTBP1-AS”):
- (i) an antisense RNA of a CTBP1 gene containing a partial sequence of the base sequence represented by SEQ ID NO:1;
- (ii) an antisense RNA of a CTBP1 gene containing the base sequence represented by SEQ ID NO:5;
- and
- (iii) a mutant or variant of the antisense RNA described above in (i) or (ii) or an antisense RNA in which one or several bases have been deleted, added, or substituted in the antisense RNA described above in (i) or (ii)
- has been expressed, comprising a CTBP1-AS expression inhibitor or function inhibitor as an active ingredient.
A method of screening growth inhibitors of cells in which CTBP1-AS has been expressed, comprising:
- bringing cells in which CTBP1-AS has been expressed or a cell extract thereof into contact with test compounds in the presence of androgen;
- measuring an expression level of CTBP1-AS;
- and
- selecting, from the test compounds, test compounds decreasing the expression level of CTBP1-AS compared with an expression level measured in the absence of the test compounds.
A method of screening proliferation inhibitors of cells in which CTBP1-AS has been expressed, comprising:
- bringing cells in which a CTBP1 gene has been expressed or a cell extract thereof into contact with test compounds in the presence of androgen;
- measuring an expression level of the CTBP1 gene;
- and
- selecting, from the test compounds, test compounds increasing the expression level of the CTBP1 gene compared with an expression level measured in the absence of the test compounds.
A testing method for evaluating the prognosis of prostate cancer, comprising:
- measuring the expression level of CTBP1-AS in cells sampled from the prostate of a patient;
- and
- comparing the expression level with an expression level in normal prostate cells.
A testing method for judging the prognosis of prostate cancer, comprising:
- measuring the expression level of a CTBP1 gene in cells sampled from the prostate of a patient;
- and
- comparing the expression level with an expression level in normal prostate cells.
Dependencies are inferred from the claim text.